Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 9/20 | 0.42 |
| ▸ | PARP1 | P09874 | 5/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6994776 | 0.79 | SLC6A4 (0.46) | HTR1ASLC6A4DRD2PARP1DRD4 | |
| SCHEMBL7038637 | 0.78 | HTR1A (0.49) | HTR1ASLC6A4DRD2PARP1DRD4 | |
| SCHEMBL6903037 | 0.74 | HTR1A (0.76) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL6323565 | 0.73 | DRD2 (0.41) | HTR1ADRD2DRD4DRD3HTR2A | |
| SCHEMBL6782983 | 0.73 | HTR1A (0.58) | HTR1ASLC6A4DRD2PARP1DRD4 | |
| SCHEMBL6322438 | 0.72 | DRD2 (0.41) | HTR1ADRD2DRD4DRD3HTR2A | |
| SCHEMBL6862712 | 0.72 | HTR1A (0.65) | HTR1ASLC6A4DRD2DRD3HTR2A | |
| SCHEMBL6628542 | 0.72 | HTR1A (0.72) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6320521 | 0.71 | DRD2 (0.67) | HTR1ADRD2DRD4DRD3HTR2A | |
| SCHEMBL6321111 | 0.70 | HTR2C (0.45) | HTR1ASLC6A4DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861434-B2 | Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one | WYETH (US) | 2005-03-01 | — | — | US | claimed |
| US-20030045526-A1 | Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one | WYETH | 2003-03-06 | — | — | US | claimed |
| WO-2002088134-A2 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 1,3,7,8-TETRAHYDRO-6,9-DIOXA-1,3-DIAZA-CYCLOPENTA[A]-NAPHTHALEN-2-ONE | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| US-6861434-B2 | Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one | WYETH (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030045526-A1 | Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2002088134-A2 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 1,3,7,8-TETRAHYDRO-6,9-DIOXA-1,3-DIAZA-CYCLOPENTA[A]-NAPHTHALEN-2-ONE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045526-A1 | Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one | SNCA, SLC6A3, DRD2 | HTR1A 20/4885SLC6A4 219/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.